Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
FAIL · Does not pass the screen
1.57 USD
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Nyxoah SA holds its Distribution at $1.57. The statistical read favours the sellers, held for 23 days.
As held on the ledger · 2025-12-31
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 23 days
Price at the screen
$1.57
Valuation
N/A trailing · -1.30 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.96
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.16%
Below 33%
Interest-bearing debt is 34.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
15.19%
Below 33%
Cash held in interest-bearing accounts and securities is 15.2% of assets, under the one-third limit.
Pass
Receivables
29.76%
Below 49%
Money owed to the company is 29.8% of assets, under the 49% limit.
Pass
Revenue purity
18.30%
Below 5%
18.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +468% from the screen price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Belgium and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NYXH trades on NASDAQ (the company is based in Belgium). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-08Markup · changed$1.57+0.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 83%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (4 analysts) rates it buy, with a mean price target of $8.
2026-08-07Distribution$1.57+12.9%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 83%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (4 analysts) rates it buy, with a mean price target of $8.
2026-07-18Distribution$1.39+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 83%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (4 analysts) rates it buy, with a mean price target of $8.
2026-07-03Distribution$1.39+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$1.39Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.